You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
|
|---|---|
| Published in |
BMC Cancer, October 2012
|
| DOI | 10.1186/1471-2407-12-482 |
| Pubmed ID | |
| Authors |
Alessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, Giulio Metro, Cecilia Nisticò, Paola Papaldo, Ferdinando De Vita, Giuliana D’Auria, Antonello Vidiri, Diana Giannarelli, Francesco Cognetti |
| Abstract |
Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT. |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 24% |
| Student > Bachelor | 6 | 16% |
| Student > Master | 5 | 14% |
| Student > Ph. D. Student | 4 | 11% |
| Other | 3 | 8% |
| Other | 5 | 14% |
| Unknown | 5 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Nursing and Health Professions | 3 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Psychology | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 6 | 16% |